Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Par Pharmaceutical, Inc. v. Hospira, Inc.

United States District Court, D. Delaware

June 21, 2019

PAR PHARMACEUTICAL, INC., PAR STERILE PRODUCTS, LLC, and ENDO PAR INNOVATION COMPANY, LLC, Plaintiffs,
v.
HOSPIRA, INC., Defendant.

          MEMORANDUM AND ORDER

          Joseph F. Bataillo, n Senior United States District Judge

         This matter is before the Court on plaintiffs Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, Inc. (collectively, “Par Pharma”) Motion in Limine to Preclude Hospira from Attempting to Re-Construe the Agreed-Upon Construction of the Claim Term “About.” D.I. 193. This is an action for patent infringement under the Hatch-Waxman Act, 21 U.S.C. § 355 and 35 U.S.C. § 271(e). The action relates to Abbreviated New Drug Application ("ANDA") No. 208908, which was filed by Hospira with the U.S. Food and Drug Administration ("FDA") seeking approval to market generic versions of Par's Adrenalin® epinephrine injection, 1 mg/mL ("the ANDA product") prior to the expiration of the patents-in-suit. In its complaint, Par Pharma alleges infringement of U.S. Patent Nos. 9, 119, 876 (“the ‘'876 patent”) and 9, 295, 657 (“the ‘'''657 patent") (together, the "patents-in-suit").

         The parties agreed to construe the term “about” as having its “[p]lain and ordinary meaning; i.e., approximately.” Hospira states it intends to prove that the plain and ordinary meaning of “about” does not extend the claimed range to cover Hospira's ANDA Product, which contains 9 mg/mL of sodium chloride.

         Par Pharma asks the Court to preclude Hospira from offering any argument or expert testimony that relies on the subsequent related prosecution of additional patents to assert that the term “about” refers to a particular numerical boundary. It contends that any such reliance would amount to improper re-arguing of claim construction. Par Pharma argues that because a claim term must be evaluated from the perspective of an ordinarily skilled artisan as of the effective filing date, subsequent prosecution history or statements would not be relevant to the inquiry.

         Hospira, Inc. (“Hospira”) contends that it does not seek to re-argue claim construction or to advance any contention “that the term ‘about' has a strict numerical limit of 8.5 mg/ml, ” but it intends to introduce evidence and elicit testimony to establish the plain and ordinary meaning of the term “about” from the perspective of a person of ordinary skill in the art (“POSA”), including statements made by the patentees in the context of the related patent application.

         Earlier in this action, the United States Magistrate Judge denied Hospira's request for leave to file a motion for summary judgment of non-infringement, noting that

[t]he parties' dispute centers on whether or not the 9 mg/mL amount of sodium chloride contained in the ANDA product falls within the scope of the claimed "in the range of about 6 to 8 mg/mL of a tonicity regulating agent" in the patents-in-suit, either for purposes of literal infringement or under the doctrine of equivalents.

         D.I. 78, Memorandum Order at 3. The Magistrate Judge relied on the parties' agreement to “construe ‘about' as having its ‘[p ]lain and ordinary meaning, i.e., approximately,' which does not expressly limit the term to ‘less than 8.5 mg/mL' of a tonicity regulating agent.” Hospira's summary judgment motion would have been premised on the contention that Hospira's ANDA Product does not contain “in the range of about 6 to 8 mg/mL of a tonicity regulating agent” because, by the inventors' own admission, the tonicity regulating agent limitation cannot stretch so far as to encompass Hospira's ANDA Product, which contains 9 mg/mL of sodium chloride as tonicity regulating agent. Hospira would have relied on four additional patent applications claiming priority to one of the asserted patents to show that “the inventors clearly and explicitly asserted to the Patent Office that a claim limitation requiring ‘in the range of about 6 to about 8 mg/mL' of a tonicity regulating agent did not encompass a formulation comprising a target concentration of 8.5 mg/mL of such an agent, because 8.5 mg/mL was outside the claimed range.” D.I. 84, Objections at 3. This Court affirmed the Magistrate Judge's finding that statements made during prosecution of two child applications filed after the issuance of the parent patents-in-suit did not reflect a binding disclaimer of claim scope. D.I. 78, Memorandum Order at 3; D.I. 103, Memorandum and Order at 4. The Magistrate Judge stated that

[f]act and expert discovery are necessary to determine whether the 9 mg/mL target amount of tonicity regulating agent in the ANDA product is "approximately" 8 mg/mL. The record reflects that Hospira allows for 96% of the nominal target amount of tonicity regulating agent, which is 8.64 mg/mL (D.I. 72, Ex. 1; Ex. 2 at Ex. A). Par should also be given the opportunity to develop a full factual record regarding whether the sodium chloride used in Hospira's ANDA product is equivalent to the claimed tonicity regulating agent.

Id. The Court noted that to do other than affirm “at this point would in fact change the current claim construction.” D.I. 103, Memorandum and Order at 4.

         The record shows there are competing expert opinions on the issue of whether Hospira's ANDA product is encompassed by the claimed range of “about 6 to 8 mg/mL, ” a limitation of each asserted claim of the two patents-in-suit. D.I. 194-1 and D.I. 194-2. To the extent the plaintiff's expert relies on subsequent prosecution history, it is only to confirm the opinions he expresses. D.I. 194-1, Expert Report at 5.

         I. LAW

         Although the motion in limine is an important tool available to the trial judge to ensure the expeditious and evenhanded management of the trial proceedings- performing a gatekeeping function and sharpening the focus for later trial proceedings- some evidentiary submissions cannot be evaluated accurately or sufficiently by the trial judge in such a procedural environment. Jonasson v. Lutheran Child and Family Servs., 115 F.3d 436, 440 (7th Cir. 1997). A motion in limine is appropriate for “evidentiary submissions that clearly ought not be presented to the jury because they clearly would be inadmissible for any purpose.” Id. In other instances, it is necessary to defer ruling until during trial, when the trial judge can better estimate the impact of the evidence. Id.

         However, trial courts should be more reluctant to exclude evidence in a bench trial than a jury trial. SeeFirst Am. State Bank v. Cont'l Ins. Co., 897 F.2d 319, 328 (8th Cir. 1990); Builders Steel Co. v. Comm'r, 179 F.2d 377, 379 (8th Cir. 1950). In bench trials, evidence should be admitted and then sifted when the district court makes its findings of fact and conclusions of law. Fields Eng'g & Equip., Inc. v. Cargill, Inc., 651 F.2d 589, 594 (8th Cir. 1981). In a nonjury case, the trial court is presumed to consider only the competent evidence. First Am. State Bank, 897 F.2d at 328. Where the court has assumed the role of fact-finder in a bench trial, “the ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.